- Home
- AKRO vs AX Comparison
AKRO vs AX Comparison
Compare AKRO & AX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- AX
- Stock Information
- Founded
- AKRO 2017
- AX 1999
- Country
- AKRO United States
- AX United States
- Employees
- AKRO N/A
- AX N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- AX Savings Institutions
- Sector
- AKRO Health Care
- AX Finance
- Exchange
- AKRO Nasdaq
- AX Nasdaq
- Market Cap
- AKRO 3.9B
- AX 4.1B
- IPO Year
- AKRO 2019
- AX 2005
- Fundamental
- Price
- AKRO $54.58
- AX $76.75
- Analyst Decision
- AKRO Strong Buy
- AX Strong Buy
- Analyst Count
- AKRO 6
- AX 6
- Target Price
- AKRO $82.50
- AX $84.00
- AVG Volume (30 Days)
- AKRO 1.8M
- AX 337.0K
- Earning Date
- AKRO 08-08-2025
- AX 07-29-2025
- Dividend Yield
- AKRO N/A
- AX N/A
- EPS Growth
- AKRO N/A
- AX 0.28
- EPS
- AKRO N/A
- AX 7.33
- Revenue
- AKRO N/A
- AX $1,181,567,000.00
- Revenue This Year
- AKRO N/A
- AX $21.51
- Revenue Next Year
- AKRO N/A
- AX $4.51
- P/E Ratio
- AKRO N/A
- AX $10.45
- Revenue Growth
- AKRO N/A
- AX 17.72
- 52 Week Low
- AKRO $21.02
- AX $54.46
- 52 Week High
- AKRO $58.40
- AX $88.46
- Technical
- Relative Strength Index (RSI)
- AKRO 68.00
- AX 69.88
- Support Level
- AKRO $53.05
- AX $74.26
- Resistance Level
- AKRO $56.49
- AX $76.28
- Average True Range (ATR)
- AKRO 2.44
- AX 1.56
- MACD
- AKRO -0.26
- AX 0.45
- Stochastic Oscillator
- AKRO 86.02
- AX 93.34
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About AX Axos Financial Inc.
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment . The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.